EBR Systems, Inc. announced the US Food and Drug Administration (FDA) approval of EBR's WiSE cardiac resynchronisation therapy ("CRT")...

RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or...

AI platform combined with autonomous labs will accelerate discovery across every domain of science Company has raised $200M in seed...

Encoded Therapeutics Reports Clinical Progress of ETX101 Gene Therapy for Dravet Syndrome, Recaps 2024 Corporate Achievements and...

City Therapeutics Forms First Major Corporate Collaboration to Advance Platform for Ophthalmic Disease Bausch + Lomb Has Rights to...

Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors VIR-5818:...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection...

New Drug Application (NDA) is based on pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib that...

Investments of up to $50 million from the Bill & Melinda Gates Foundation to develop globally accessible in vivo genetic therapies for...